Clinical trial · Interventional
Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment
Double-blind Randomized Prospective Phase III Study of a Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment of the Postoperative Pain From Hospital to Home
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment defect
Summary
Brief summary (as posted)
The acute pain care, in particular after breast cancer surgery must be early and quickly effective, because a severe postoperative pain increases the risk of chronic pain and exposes to a risk of important embarrassment for the realization of simple daily movements. Associated to conventional analgesics administered by systemic way, a local anesthesic (ropivacaine) can be continuously infused (Continues Cicatricial Perfusion CCP) in the operating wound by a multi-drilled catheter by means of a elastomeric diffuser set up in the surgical unit by the surgeon at the end the surgical procedure. Besides the control of the postoperative acute pain, the local anesthesic could intervene in the prevention of the chronic pain, the early recovery, the reduction of the neuropathic pains and the decrease of needs in morphine after mastectomy. The duration of hospitalization being lower than 48 hours for this type of surgery, the investigators envisage an immediate follow-up in the Units of Care then at home, what will require a training of the hospital actors and at home (patient, family, visiting nurse, general practitioner). Although proposed for several years, the CCP after breast surgery is still a little spread technique and few works had evaluated the pain at rest and at mobilization after mastectomy, the early rehabilitation, and to spread its use towards home, that is why we propose a randomized double-blind study ropivacaine / placebo in patients after mastectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| physiological saline | Drug | — | UNRESOLVED |
| Ropivacaine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ropivacaine
- description
- Ropivacaine
- interventionNames
- Drug: Ropivacaine
- type
- PLACEBO_COMPARATOR
- label
- placebo
- description
- physiological saline
- interventionNames
- Drug: physiological saline
Primary outcomes (1)
- measure
- Delay to obtain the three criteria of premature recovery after mastectomy
- timeFrame
- time from surgery up to 6 months (At day of surgery, and at day 1, day 2, day 3 and day 15, then at month 3 and month 6).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women \> 18 years, * Operated for a breast cancer by mastectomy with or without lymph node dissection, without immediate reconstruction, * Capable of understanding the antalgic protocol, * No contraindication to the local anesthesics, * Social security affiliation, * Signed informed consent. Exclusion Criteria: * Preoperative radiotherapy, * Local infection, * Contra-indication to the local anesthetic or to CCP, * Contra-indication for the use of morphine, * Contra-indication for the use of remifentanil, * Addiction to opioid analgesics know or not, * Allergy to local anesthetics, * Hepatic or renal impairment grim known, * Previous surgery on the operated breast, * Pregnant women, or child-bearing potential, or lactating women, * Patient deprived of liberty or under supervision of a guardian.
References
Publications (1)
- RESULTRiff C, Guilhaumou R, Marsot A, Beaussier M, Cohen M, Blin O, Francon D. Ropivacaine Wound Infiltration for Pain Management After Breast Cancer Mastectomy: A Population Pharmacokinetic Analysis. Clin Pharmacol Drug Dev. 2018 Nov;7(8):811-819. doi: 10.1002/cpdd.452. Epub 2018 Apr 16. PMID 29659182